Aldena Therapeutics, a private biotech company pioneering siRNA-based therapies for dermatological indications, has selected PCI Pharma Services, a global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions. ALD-102 is currently in preclinical trials and represents the most advanced therapy in Aldena’s pipeline.

PCI specializes in development and manufacturing, clinical trial services, advanced drug delivery and commercial technology services. Aldena chose PCI because of its expertise in complex formulations, and cold chain. PCI’s robotic sterile fill-finish gloveless isolator platform can be used to fill various sterile medications into vials and syringes for small-to-mid size client needs. The equipment, paired with PCI’s services and global network, comprises PCI’s Speed to Study offering, which aims to decrease the average turnaround time from proposal signing to the injectable product’s distribution for clinical trial use.

The Microcell Vial Filler and SA25 Aseptic Filling Workcell at PCI’s San Diego facility provides the delivery of medicines from phase I through phase III, supporting local and global clinical client needs.

“We are very pleased as Aldena’s agreement with PCI has given us the integrated services and support, we need to meet our ambitious research and development timelines,” said Thibaud Portal, CEO of Aldena. “This collaboration with PCI will be essential as we continue building our pipeline of new dermatological products targeting conditions for which there is an unmet medical need.”

Salim Haffar, CEO of PCI Pharma Services said, “We are proud to be one of only a few CDMOs worldwide able to offer integrated sterile fill-finish capabilities, alongside our clinical packaging facilities, to clients who are developing novel and disruptive approaches to treating disease. Working with innovative companies like Aldena directly ladders back to our mission to provide clinical and commercial supply chain solutions to ultimately improve patients’ lives.”